Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ninervir-200
- Development stage
- Unknown
- Lead developer
- Niner Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ninervir (Ninervir-200) is an oral generic version of molnupiravir, a nucleoside analogue prodrug developed for the treatment of COVID-19. It is metabolized to the active ribonucleoside analog N4-hydroxycytidine (NHC), which is then phosphorylated to NHC-triphosphate. This active form is incorporated into viral RNA by the SARS-CoV-2 RNA-directed RNA polymerase (RdRp), leading to an accumulation of mutations in the viral genome, a process known as viral error catastrophe or lethal mutagenesis. This mechanism effectively inhibits viral replication. Ninervir is marketed by Niner Pharmaceuticals as a treatment for mild-to-moderate COVID-19 in adults at high risk for progression to severe disease.
- Brand names
- Ninervir-200Ninervir200Ninervir 200Ninervir
- Other names
- molnupiravir
Beyond the preview
Go deeper on Ninervir-200.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ninervir-200.